|Day Low/High||68.10 / 68.82|
|52 Wk Low/High||65.06 / 100.23|
NORTH CHICAGO, Ill., April 3, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its first-quarter 2019 financial results on Thursday, April 25 before the market opens.
-This marks the first regulatory approval globally for SKYRIZI™ (risankizumab)
NORTH CHICAGO, Ill., March 19, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.
- The Phase 3 CLL14 trial of venetoclax in combination with obinutuzumab is the first randomized clinical trial to examine a chemotherapy-free treatment given for a fixed duration in previously-untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities
It's no secret why the list of S&P 500 'dividend aristocrats' is a who's-who of great Wall Street brands. Here's what makes them so special.
NORTH CHICAGO, Ill., March 1, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019.
- CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission(1-3)
Experts offer their top stock ideas in oncology detection and treatment.
The most recent short interest data has been released for the 02/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Jim Cramer says if you focus on what's going right, you'll sleep better and do a lot better with your money, too.
Jim Cramer weighs in on Waste Management, Weight Watchers, Centene, Aurinia Pharmaceuticals, Activision Blizzard, AbbVie, Cronos Group and more.
- Nineteen abstracts underscore AbbVie's continued pursuit of research on behalf of patients living with chronic dermatologic conditions
AbbVie to provide multi-million-dollar financing to Voyager to develop and commercialize potential Parkinson's treatment.
- Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein
- Upadacitinib, an investigational once-daily oral JAK1-selective inhibitor, is being studied for the treatment of adult patients with moderate to severe rheumatoid arthritis[1-8]
NORTH CHICAGO, Ill. and MENLO PARK, Calif.
SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against the following companies: AbbVie Inc.
Of the 57 index constituents, four Aristocrats have yields above 4.0%.
Jim Cramer says that if expectations are too high, even a great quarter cannot save you from the wave of selling.
Jim Cramer takes a look at Carvana, Bank OZK, Idexx Labs, Patterson-UTI Energy, 3D Systems, AbbVie and more.
- Milestone marks the 10th FDA approval for IMBRUVICA in six different disease areas since 2013
Stocks rose by Friday's close, getting a boost from a number of strong corporate earnings reports even as investors continue to worry about a lack of progress in U.S.-China trade talks.
The pharmaceutical company reports fourth-quarter results below analysts' consensus forecasts.
China's central bank announced a bill swap mechanism late Thursday aimed at slowing down the nation's economic slowdown.
- Reports Full-Year Diluted EPS of $3.66 on a GAAP Basis; Adjusted Diluted EPS of $7.91 Reflects Growth of 41.3 Percent
One of pharma's biggest CEO's talks M&A action on the exchange.
Jim Cramer talks about the Fed, and outlines your game plan.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.